<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02984384</url>
  </required_header>
  <id_info>
    <org_study_id>PCS-1511-32745</org_study_id>
    <nct_id>NCT02984384</nct_id>
  </id_info>
  <brief_title>PREVENTion of Clot in Orthopaedic Trauma</brief_title>
  <acronym>PREVENT CLOT</acronym>
  <official_title>PREVENTion of Clot in Orthopaedic Trauma (PREVENT CLOT): A Randomized Pragmatic Trial Comparing the Complications and Safety of Blood Clot Prevention Medicines Used in Orthopaedic Trauma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Major Extremity Trauma Research Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Major Extremity Trauma Research Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare aspirin versus low-molecular weight heparin (LMWH)&#xD;
      (Enoxaparin) as a thromboprophylaxis in patients who sustain a fracture.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who sustain orthopaedic trauma are at an increased risk of venous thromboembolism&#xD;
      (VTE), including fatal pulmonary embolism (PE). Current guidelines recommend&#xD;
      low-molecular-weight heparin (LMWH) for VTE prophylaxis in orthopaedic trauma patients.&#xD;
      However, emerging literature in total joint arthroplasty patients suggests the potential&#xD;
      clinical benefits of VTE prophylaxis with aspirin. This trial aims to determine if aspirin is&#xD;
      non-inferior to LMWH for thromboprophylaxis in fracture patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cause-specific death</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal pulmonary embolism</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deep vein thrombosis</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complication</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound complication</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deep surgical site infection</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12200</enrollment>
  <condition>Blood Clot</condition>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>Low Molecular Weight Heparin (LMWH)-Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of 30 mg enoxaparin, twice a day via injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetylsalicylic acid (ASA)-Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enteral ingestion or administration of 81 mg ASA, twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.</description>
    <arm_group_label>Acetylsalicylic acid (ASA)-Aspirin</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Molecular Weight Heparin (LMWH)</intervention_name>
    <description>The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.</description>
    <arm_group_label>Low Molecular Weight Heparin (LMWH)-Enoxaparin</arm_group_label>
    <other_name>Enoxaparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ Patients who have a planned operative or non-operative pelvis or acetabular fracture, or&#xD;
        any operative extremity fracture proximal to the metatarsals or carpals.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who present to the hospital more than 48 hours post injury&#xD;
&#xD;
          -  Patients who received more than 2 doses of LMWH or aspirin for initial VTE prophylaxis&#xD;
&#xD;
          -  Patients on long term blood thinners (other than low-dose aspirin or platelet&#xD;
             inhibitors such as Plavix or Aggrenox)&#xD;
&#xD;
          -  Patients who have had a VTE within the last 6 months&#xD;
&#xD;
          -  Patients on therapeutic (as opposed to prophylactic) blood thinners for an acute issue&#xD;
             at the time of admission&#xD;
&#xD;
          -  Patients who have a newly diagnosed indication for therapeutic blood thinners (for&#xD;
             example vascular injury) that will require therapeutic anticoagulation for more than&#xD;
             one week&#xD;
&#xD;
          -  Patients who cannot receive either of the study medications due to an allergy (history&#xD;
             of heparin induced thrombocytopenia, allergy to aspirin, or NSAIDs) or other medical&#xD;
             contraindication to blood thinners&#xD;
&#xD;
          -  Patients who are on higher dose aspirin (&gt;81 mg once a day or higher) for medical&#xD;
             reasons or who will be treated with higher dose aspirin&#xD;
&#xD;
          -  Patients with underlying chronic clotting disorders (i.e. Factor V Leiden,&#xD;
             hyperhomocysteinemia, Protein C and S deficiency) that require full dose&#xD;
             anticoagulation or are a contraindication to venous thromboembolism chemoprophylaxis&#xD;
&#xD;
          -  Patients with end stage renal disease or impaired creatinine clearance &lt;30 ml/min at&#xD;
             time of randomization(note: creatinine clearance does not need to be documented if&#xD;
             prescribing physician would order medication without test as SOC)&#xD;
&#xD;
          -  Pregnant or lactating patients&#xD;
&#xD;
          -  Patients contraindicated for any reason for either medicine&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Patients who do not speak either English or Spanish&#xD;
&#xD;
          -  Patients may be excluded for other reasons at the discretion of the treating&#xD;
             physician; the reason for exclusion must be documented on the screening form&#xD;
&#xD;
          -  Patients who have a known COVID-19 diagnosis prior to fracture treatment or within 3&#xD;
             months of the index fracture.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert O'Toole, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renan Castillo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tara Taylor, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katherine Frey, PhD, MPH, RN</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tara Taylor, MPH</last_name>
    <phone>410-614-6081</phone>
    <email>ttaylo56@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathan O'Hara, MHA</last_name>
    <email>nohara@umoa.umm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Seach</last_name>
      <email>aseach@email.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Christina Boulton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bellal Joseph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Ryder Trauma Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Napuri</last_name>
      <email>kxn254@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Zych, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rishi Rattan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lakye Deeter</last_name>
      <email>lakedwar@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Gaski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland R Adams Cowley Shock Trauma Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmin Degani</last_name>
      <email>ydegani@umoa.umm.edu</email>
    </contact>
    <investigator>
      <last_name>Robert O'Toole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deborah Stein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael McTague</last_name>
      <email>mmctague@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Weaver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Velmahos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Allbritton</last_name>
      <email>sqallbritton@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Partrick Bergin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Kutcher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Ressler</last_name>
      <email>Daniel.R.Ressler@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Leah Gitajn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kurt Rhynhart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Seymour, PhD</last_name>
      <email>Rachel.Seymour@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Michael Bosse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashley Christmas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Holden</last_name>
      <email>mholden@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Eben Carroll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Preston Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Breslin</last_name>
      <email>mbreslin@metrohealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Joanne Fraifogl</last_name>
      <email>jfraifogl@metrohealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Heather Vallier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffery Claridge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci Salopek</last_name>
      <email>traci.salopek@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Gregory Altman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital, Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Jean Crisco</last_name>
      <email>mjcrisco@universityorthopedics.com</email>
    </contact>
    <investigator>
      <last_name>Roman Hayda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Lueckal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee, RegionOne Medical Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynda Waddle-Smith</last_name>
      <email>lwaddle@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>John Weinlein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Croce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Trochez</last_name>
      <email>karen.m.trochez@Vanderbilt.Edu</email>
    </contact>
    <investigator>
      <last_name>William Obremskey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oscar Guillamondegui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayank Rao</last_name>
      <email>mayank.rao@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>April Vanderslice</last_name>
      <email>april.vanderslice@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joshua Gary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bryan Cotton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Herrera</last_name>
      <email>maria.i.herrera6.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Patrick Osborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kurt Edwards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lolita Ramsey, PhD</last_name>
      <email>lolita.ramsey@inova.org</email>
    </contact>
    <investigator>
      <last_name>Robert Hymes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Agel</last_name>
      <email>bagel@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Reza Firoozabadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Cuschieri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Johnson</last_name>
      <email>otrc@ortho.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Whiting, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary, Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Lienhard</last_name>
      <email>karin.lienhard@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Prism Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul McBeth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster University, Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johal Herman, MD</last_name>
      <email>hermanjohal@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Johal Herman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 2, 2016</study_first_submitted>
  <study_first_submitted_qc>December 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trauma</keyword>
  <keyword>Blood clot</keyword>
  <keyword>Venous Thromboembolism</keyword>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Deep Vein Thrombosis</keyword>
  <keyword>Thromboprophylaxis</keyword>
  <keyword>Blood clot prevention</keyword>
  <keyword>trauma patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

